Zydus gets US FDA marketing approval for tizanidine tablets to treat muscle spasms
Zydus Cadila, an innovative, global pharmaceutical company, has received the final approval from the US FDA to market tizanidine tablets USP in the strengths of 2 mg and 4 mg.
Tizanidine is used to treat muscle spasms caused by certain conditions such as multiple sclerosis, spinal cord injury and works by helping to relax the muscles. It will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad.
The group now has more than 180 approvals and has so far filed over 320 ANDAs since the commencement of the filing process in FY 2003-04.